PRDX4 and hepatocellular carcinoma: PRDX4 is overexpressed in a variety of tumor tissues (Jia et al., 2019), and inhibits anoikis resistance through the β-catenin/ID2 pathway, thereby promoting the growth and metastasis of hepatocellular carcinoma cells (Wang et al., 2019).